pharmaceutical investing Avid Bioservices Selected as Commercial Manufacturer for Critical Enzyme Replacement Therapy by a Subsidiary of Roivant Sciences
Alvopetro Announces Q3 2026 Dividend of US$0.12 Per Share and Supplementary Information on December 31, 2025 Prospective Resources
Skyharbour Partner Company Purecore Commences Data Compilation and Target Generation at The Yurchison Uranium Property
